BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 2581259)

  • 21. Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes.
    Pangburn MK; Schreiber RD; Trombold JS; Müller-Eberhard HJ
    J Exp Med; 1983 Jun; 157(6):1971-80. PubMed ID: 6222136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunocytochemical staining of decay-accelerating factor (DAF) on erythrocytes: paroxysmal nocturnal hemoglobinuria (PNH)].
    Kobayashi T; Nakazawa M; Sato Y; Tomiyama J; Ninomiya H; Abe T; Terasawa T; Shichishima T; Fujita T
    Rinsho Ketsueki; 1992 Feb; 33(2):162-6. PubMed ID: 1378912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo.
    Devine DV; Siegel RS; Rosse WF
    J Clin Invest; 1987 Jan; 79(1):131-7. PubMed ID: 2432087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aurin tricarboxylic acid protects against red blood cell hemolysis in patients with paroxysmal nocturnal hemoglobinemia.
    Lee M; Narayanan S; McGeer EG; McGeer PL
    PLoS One; 2014; 9(1):e87316. PubMed ID: 24489894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.
    Holguin MH; Wilcox LA; Bernshaw NJ; Rosse WF; Parker CJ
    J Clin Invest; 1989 Nov; 84(5):1387-94. PubMed ID: 2478585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
    Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
    J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by acid-activated serum.
    Hänsch G; Hammer C; Jiji R; Rother U; Shin M
    Immunobiology; 1983 Mar; 164(2):118-26. PubMed ID: 6852860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Paroxysmal nocturnal hemoglobinuria (PNH) deficiency of major complement-regulatory membrane proteins on erythrocytes].
    Ninomiya H; Kobayashi T; Abe T
    Rinsho Ketsueki; 1991 Jun; 32(6):612-7. PubMed ID: 1716325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement sensitivity of erythrocytes in a patient with inherited complete deficiency of CD59 or with the Inab phenotype.
    Shichishima T; Saitoh Y; Terasawa T; Noji H; Kai T; Maruyama Y
    Br J Haematol; 1999 Feb; 104(2):303-6. PubMed ID: 10050712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deficiency of the complement regulatory protein, "decay-accelerating factor," on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria.
    Nicholson-Weller A; Spicer DB; Austen KF
    N Engl J Med; 1985 Apr; 312(17):1091-7. PubMed ID: 3845321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.
    Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC
    Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
    Davitz MA; Low MG; Nussenzweig V
    J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
    Parker CJ; Baker PJ; Rosse WF
    J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deficiency of glycosyl-phosphatidylinositol anchored proteins on paroxysmal nocturnal haemoglobinuria (PNH) neutrophils and monocytes: heterogeneous deficiency of decay-accelerating factor (DAF) and CD16 on PNH neutrophils.
    Kawakami Z; Ninomiya H; Tomiyama J; Abe T
    Br J Haematol; 1990 Apr; 74(4):508-13. PubMed ID: 1693286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A simplified assay for the specific diagnosis of paroxysmal nocturnal hemoglobinuria: detection of DAF(CD55)- and HRF20(CD59)- erythrocytes in microtyping cards.
    Nilsson B; Hagström U; Englund A; Säfwenberg J
    Vox Sang; 1993; 64(1):43-6. PubMed ID: 7680511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes. Studies on C9 binding and incorporation into high molecular weight complexes.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Exp Med; 1986 Oct; 164(4):981-97. PubMed ID: 3760783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis of paroxysmal nocturnal haemoglobinuria by phenotypic analysis of erythrocytes using two-colour flow cytometry with monoclonal antibodies to DAF and CD59/MACIF.
    Shichishima T; Terasawa T; Saitoh Y; Hashimoto C; Ohto H; Maruyama Y
    Br J Haematol; 1993 Oct; 85(2):378-86. PubMed ID: 7506570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.
    Lindorfer MA; Pawluczkowycz AW; Peek EM; Hickman K; Taylor RP; Parker CJ
    Blood; 2010 Mar; 115(11):2283-91. PubMed ID: 20068220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogenous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes.
    Shichishima T; Terasawa T; Hashimoto C; Ohto H; Uchida T; Maruyama Y
    Br J Haematol; 1991 Aug; 78(4):545-50. PubMed ID: 1716957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of complement-mediated lysis of dithiothreitol-treated erythrocytes involves increased C9 insertion and polymerization.
    Hu VW; Mazorow DL; Nicholson-Weller A; Shin ML
    Mol Immunol; 1987 Aug; 24(8):887-96. PubMed ID: 2821389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.